Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q3 2021
Institutional positions in Protagonist Therapeutics, Inc as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 132
- −6 vs. Q2 2021
- Shares held
- 46.4M
- +694.4K (+1.5%) vs. Q2 2021
- Total value
- $820.8M
- −$1.22B (−59.9%) vs. Q2 2021
- New holders
- 25
- 59 more added
- Sold out
- 31
- 34 more reduced
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTGX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 346 | $9.30B |
| Q1 2026 | 322 | $8.31B |
| Q4 2025 | 319 | $6.18B |
| Q3 2025 | 275 | $4.70B |
| Q2 2025 | 274 | $3.92B |
| Q1 2025 | 275 | $3.15B |
| Q4 2024 | 241 | $2.44B |
| Q3 2024 | 240 | $2.78B |
| Q2 2024 | 188 | $2.05B |
| Q1 2024 | 185 | $1.73B |
| Q4 2023 | 157 | $1.32B |
| Q3 2023 | 144 | $945.9M |
| Q2 2023 | 167 | $1.57B |
| Q1 2023 | 138 | $1.22B |
| Q4 2022 | 137 | $533.3M |
| Q3 2022 | 133 | $398.9M |
| Q2 2022 | 131 | $422.1M |
| Q1 2022 | 140 | $1.19B |
| Q4 2021 | 149 | $1.68B |
| Q3 2021 | 132 | $820.8M |
| Q2 2021 | 139 | $2.16B |
| Q1 2021 | 127 | $1.15B |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Protagonist Therapeutics, Inc; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 218,936 | $3.88M | 0.02% | +99,733+83.7% | Added |
| Sphera Funds Management Ltd. | 260,379 | $4.61M | 0.46% | −42,586−14.1% | Reduced |
| Susquehanna International Group, LLP | 267,383 | $4.74M | 0.01% | +246,050+1,153.4% | Added |
| Sofinnova Investments, Inc. | 297,709 | $5.28M | 0.34% | −151,373−33.7% | Reduced |
| Adage Capital Partners GP, L.L.C. | 300,045 | $5.32M | 0.01% | −250,000−45.5% | Reduced |
| Charles Schwab Investment Management Inc | 309,832 | $5.49M | 0.00% | +28,454+10.1% | Added |
| Opaleye Management Inc. | 330,222 | $5.85M | 1.09% | 00.0% | Unchanged |
| Altium Capital Management LP | 346,000 | $6.13M | 1.64% | +63,555+22.5% | Added |
| Goldman Sachs Group Inc | 423,195 | $7.50M | 0.00% | +31,252+8.0% | Added |
| JPMorgan Chase & Co | 428,695 | $7.60M | 0.00% | −4,733−1.1% | Reduced |
| Northern Trust Corp | 456,977 | $8.10M | 0.00% | +12,392+2.8% | Added |
| Morgan Stanley | 474,315 | $8.40M | 0.00% | +404,485+579.2% | Added |
| Price T Rowe Associates Inc | 491,641 | $8.71M | 0.00% | −494,613−50.2% | Reduced |
| Commodore Capital LP | 498,079 | $8.83M | 2.33% | +287,479+136.5% | Added |
| Millennium Management LLC | 522,871 | $9.27M | 0.01% | +507,431+3,286.5% | Added |
| Voloridge Investment Management, LLC | 550,083 | $9.75M | 0.06% | +543,579+8,357.6% | Added |
| Geode Capital Management, LLC | 728,930 | $12.9M | 0.00% | +15,092+2.1% | Added |
| Obermeyer Wood Investment Counsel, LLLP | 776,689 | $13.8M | 0.76% | +15,671+2.1% | Added |
| Deutsche Bank AG | 823,290 | $14.6M | 0.01% | +1,568+0.2% | Added |
| Dimensional Fund Advisors LP | 875,732 | $15.5M | 0.00% | +84,716+10.7% | Added |
| Deerfield Management Company, L.P. (Series C) | 1,394,000 | $24.7M | 0.48% | +31,210+2.3% | Added |
| EcoR1 Capital, LLC | 1,443,800 | $25.6M | 0.90% | +1,443,800 | New |
| Artal Group S.A. | 1,500,000 | $26.6M | 0.65% | +1,500,000 | New |
| RTW Investments, LP | 1,753,695 | $31.1M | 0.47% | −1,753,695−50.0% | Reduced |
| State Street Corp | 2,013,979 | $35.7M | 0.00% | +559,359+38.5% | Added |
| Vanguard Group Inc | 2,353,786 | $41.7M | 0.00% | +65,752+2.9% | Added |
| Farallon Capital Management, L.L.C. | 2,392,000 | $42.4M | 0.23% | +62,320+2.7% | Added |
| Johnson & Johnson | 2,449,183 | $43.4M | 3.81% | +2,449,183 | New |
| BlackRock Inc. | 3,199,496 | $56.7M | 0.00% | +158,955+5.2% | Added |
| BVF Inc | 3,901,759 | $69.1M | 2.70% | +147,664+3.9% | Added |
| Point72 Asset Management, L.P. | 4,387,300 | $77.7M | 0.37% | +3,232,100+279.8% | Added |
| FMR LLC | 6,492,638 | $115.0M | 0.01% | −623,745−8.8% | Reduced |
| Consonance Capital Management LP | 0 | $0 | 0.00% | −3,446,874−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −845,199−100.0% | Sold out |
| Novo Holdings A/S | 0 | $0 | 0.00% | −600,010−100.0% | Sold out |
| Loomis Sayles & Co L P | 0 | $0 | 0.00% | −536,920−100.0% | Sold out |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −455,276−100.0% | Sold out |
| Tri Locum Partners LP | 0 | $0 | 0.00% | −341,650−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −337,109−100.0% | Sold out |
| Pinz Capital Management, LP | 0 | $0 | 0.00% | −196,000−100.0% | Sold out |
| International Biotechnology Trust PLC | 0 | $0 | 0.00% | −152,000−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −140,100−100.0% | Sold out |
| Lord, Abbett & Co. LLC | 0 | $0 | 0.00% | −138,608−100.0% | Sold out |
| Parkman Healthcare Partners LLC | 0 | $0 | 0.00% | −130,000−100.0% | Sold out |
| Emerald Advisers, LLC | 0 | $0 | 0.00% | −103,850−100.0% | Sold out |
| EAM Investors, LLC | 0 | $0 | 0.00% | −101,019−100.0% | Sold out |
| Iszo Capital Management LP | 0 | $0 | 0.00% | −93,883−100.0% | Sold out |
| Emerald Mutual Fund Advisers Trust | 0 | $0 | 0.00% | −76,965−100.0% | Sold out |
| EAM Global Investors LLC | 0 | $0 | 0.00% | −70,185−100.0% | Sold out |
| Gyon Technologies Capital Management, LP | 0 | $0 | 0.00% | −35,056−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −33,230−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −19,986−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −16,540−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −13,939−100.0% | Sold out |
| Amalgamated Bank | 0 | $0 | 0.00% | −7,807−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −5,431−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Gotham Asset Management, LLC | 0 | $0 | 0.00% | −4,793−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −4,710−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −2,731−100.0% | Sold out |
| Hartford Financial Management Inc. | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Johnson & Johnson Innovation - JJDC, Inc. | – | – | – | – | Not filed |